These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30052091)

  • 1. Does public perception bias lead to more frequent reporting of adverse events: branded vs generic drugs.
    Qian J; Mishuk AU; Hansen RA
    Expert Opin Drug Saf; 2018 Aug; 17(8):753-756. PubMed ID: 30052091
    [No Abstract]   [Full Text] [Related]  

  • 2. Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications.
    Alatawi Y; Rahman MM; Cheng N; Qian J; Peissig PL; Berg RL; Page CD; Hansen RA
    J Clin Pharm Ther; 2018 Jun; 43(3):327-335. PubMed ID: 29092097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA
    Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
    Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
    Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System.
    Serebruany VL; Hall TS; Atar D; Agewall S; Hyun Kim M; Geudelin B; Lomakin N; Marciniak TA
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):210-215. PubMed ID: 30192939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adverse drug reactions reporting is helping "non substituable" prescription!].
    Jacquot J; Bagheri H; Montastruc JL
    Therapie; 2014; 69(3):259-61. PubMed ID: 24927508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA mulls changes to bioequivalence standards.
    Traynor K
    Am J Health Syst Pharm; 2010 Jun; 67(11):864. PubMed ID: 20484205
    [No Abstract]   [Full Text] [Related]  

  • 9. An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System.
    Iyer G; Marimuthu SP; Segal JB; Singh S
    Drug Saf; 2017 Sep; 40(9):799-808. PubMed ID: 28593504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases.
    Park-Wyllie L; van Stralen J; Castillon G; Sherman SE; Almagor D
    Clin Ther; 2017 Oct; 39(10):2006-2023. PubMed ID: 28988700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names.
    Chao J; Skup M; Alexander E; Tundia N; Macaulay D; Wu E; Mulani P
    Adv Ther; 2015 Mar; 32(3):270-83. PubMed ID: 25772256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug.
    Hansen RA; Qian J; Berg RL; Linneman JG; Seoane-Vazquez E; Dutcher S; Raofi S; Page CD; Peissig PL
    Clin Pharmacol Ther; 2018 Feb; 103(2):310-317. PubMed ID: 27981563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA moves closer to new requirements for NTI drugs.
    Traynor K
    Am J Health Syst Pharm; 2011 Sep; 68(17):1568-9, 1570. PubMed ID: 21856797
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy.
    Makus KG; McCormick J
    Clin Ther; 2007 Feb; 29(2):334-41. PubMed ID: 17472825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs.
    Cheng N; Rahman MM; Alatawi Y; Qian J; Peissig PL; Berg RL; Page CD; Hansen RA
    Drug Saf; 2018 Apr; 41(4):363-376. PubMed ID: 29196989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower Proportion of Spontaneous Adverse Event Reports for Generic Drugs by Comparison With Original Branded Drugs at the Postmarket Stage in Japan.
    Takami A; Hirata K; Ishiguro C; Hanaoka H; Uyama Y
    Clin Pharmacol Ther; 2019 Jun; 105(6):1471-1476. PubMed ID: 30588617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs.
    Hansen RA; Qian J; Berg R; Linneman J; Seoane-Vazquez E; Dutcher SK; Raofi S; Page CD; Peissig P
    Pharmacotherapy; 2017 Apr; 37(4):429-437. PubMed ID: 28152215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multinational medicines--ensuring drug quality in an era of global manufacturing.
    Okie S
    N Engl J Med; 2009 Aug; 361(8):737-40. PubMed ID: 19692686
    [No Abstract]   [Full Text] [Related]  

  • 19. Active and passive surveillance of enoxaparin generics: a case study relevant to biosimilars.
    Grampp G; Bonafede M; Felix T; Li E; Malecki M; Sprafka JM
    Expert Opin Drug Saf; 2015 Mar; 14(3):349-60. PubMed ID: 25557261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Branded versus generic clopidogrel in cardiovascular diseases: a systematic review.
    Caldeira D; Fernandes RM; Costa J; David C; Sampaio C; Ferreira JJ
    J Cardiovasc Pharmacol; 2013 Apr; 61(4):277-82. PubMed ID: 23188124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.